Company news

Replimune Group, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Replimune to Present at the William Blair Biotech Focus Conference 2021

July 6, 2021

Replimune Provides Data Update from its RP1 (vusolimogene oderparepvec) and RP2 Programs and Announces Plans to Expand the Development of RP2/3 Beyond Phase 1

June 2, 2021

Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update

May 19, 2021

Replimune Appoints Tanya Lewis as Chief Development Operations Officer

May 9, 2021

Replimune Provides a Regulatory Update for its Registration- Directed Clinical Trials Evaluating RP1 in Combination with Libtayo® (cemiplimab) for the Treatment of CSCC & Evaluating RP1 in Combination with Opdivo® (nivolumab) in anti-PD1 Failed Melanoma

May 4, 2021

Replimune to Host Virtual Investor Event on June 3, 2021

April 27, 2021

Replimune Appoints Genentech Global Oncology Franchise Head Sushil Patel, Ph.D. as Chief Commercial Officer

April 20, 2021

Replimune to Present New Biomarker & Pre-clinical Data for Lead Oncolytic Immunotherapy Programs at the 2021 American Association for Cancer Research Annual Meeting

April 11, 2021

Replimune to Present at the American Association for Cancer Research Annual Meeting 2021

March 10, 2021

Replimune to Present at the SVB Leerink 10th Annual Global Healthcare Conference

February 17, 2021

Replimune Provides 2020 Year End Review and Overview of Expected 2021 Milestones

January 10, 2021

Replimune to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 5, 2021

Replimune Announces First Patient Dosed with RP3 in a Phase 1 Clinical Trial in Patients with Advanced Solid Tumors

January 4, 2021

Replimune to Participate at the SVB Leerink Oncology 1x1 Day

November 11, 2020

Replimune Announces Poster Presentations at the SITC 2020 Annual Meeting and a Presentation at the SITC 2020 Annual Meeting Virtual Press Conference

November 8, 2020

Replimune Releases Updated Corporate Presentation

October 19, 2020

Replimune Appoints Tanya Lewis to the Board of Directors

October 18, 2020

Replimune Announces Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 13, 2020

Replimune to Participate at the Chardan Virtual 4th Annual Genetic Medicines Conference

September 30, 2020

Replimune Appoints Andrea Pirzkall, M.D. as Chief Medical Officer

July 21, 2020

Biodesix Appoints Jean Franchi and Hany Massarany to Board of Directors

July 19, 2020

Replimune to Participate at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference

June 16, 2020

Replimune Reports Fiscal Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

June 2, 2020

Replimune Provides RP1 Data Update from its Phase 2 Cohorts in Melanoma and Non-Melanoma Skin Cancer that Strongly Support Replimune’s Ongoing Registration-Directed Clinical Trials with RP1

June 2, 2020

Replimune to Provide Data Update on June 3, 2020

April 29, 2020

Replimune Appoints Dieter Weinand as Chairman and Paolo Pucci to the Board of Directors

April 1, 2020

Replimune Provides 2019 Year End Corporate Update and Reviews Expected 2020 Milestones

January 12, 2020

Replimune Announces the Evolution of its Management Team as it Advances Through Later Stage Clinical Development and Prepares for Commercialization

January 8, 2020

Replimune to Present at the 38th Annual J.P.Morgan Healthcare Conference

January 6, 2020

Replimune Strengthens Executive Team with the Appointment of Jean Franchi as Chief Financial Officer

December 8, 2019

Replimune to Present at the Piper Jaffray 31st Annual Healthcare Conference

November 25, 2019

Replimune Reports Second Fiscal Quarter Financial Results and Provides Corporate Update

November 10, 2019

Replimune Presents Initial Clinical Data with RP1 that Strongly Supports Expansion of Clinical Programs in Melanoma and Cutaneous Squamous Cell Carcinoma (CSCC)

November 7, 2019

Replimune to Host Investor Event at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

October 30, 2019

Replimune Announces First Patient Enrolled in Phase 1 Clinical Trial of RP2 Alone and in Combination with Opdivo® in Advanced Cancer Patients

October 23, 2019

Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma

October 14, 2019

Replimune Announces Presentation at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

October 1, 2019

Replimune to Present at Chardan’s 3rd Annual Genetic Medicines Conference

September 30, 2019

← Newer news releases

Calls

Decks

The 5 newest of 9 decks. Every deck is listed under its year.